Camurus AB (publ) (STO: CAMX)

Market Cap	32.02B
Revenue (ttm)	1.69B
Net Income (ttm)	266.21M
Shares Out	58.81M
EPS (ttm)	4.51
PE Ratio	120.87
Forward PE	41.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,236
Open	545.00
Previous Close	546.00
Day's Range	530.00 - 552.50
52-Week Range	417.40 - 715.00
Beta	0.93
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 213
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CAMX

Financial Performance

In 2023, Camurus AB's revenue was 1.72 billion, an increase of 79.52% compared to the previous year's 956.34 million. Earnings were 431.44 million, an increase of 676.63%.